Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Secular trends of sustained remission in rheumatoid arthritis, a nationwide study in Sweden.

Einarsson JT, Willim M, Saxne T, Geborek P, Kapetanovic MC.

Rheumatology (Oxford). 2019 Jul 13. pii: kez273. doi: 10.1093/rheumatology/kez273. [Epub ahead of print]

PMID:
31302705
2.

Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren's syndrome without disease modifying treatment.

Nived P, Saxne T, Geborek P, Mandl T, Skattum L, Kapetanovic MC.

BMC Rheumatol. 2018 Apr 5;2:12. doi: 10.1186/s41927-018-0019-6. eCollection 2018.

3.

Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden.

Einarsson JT, Willim M, Ernestam S, Saxne T, Geborek P, Kapetanovic MC.

Rheumatology (Oxford). 2019 Feb 1;58(2):227-236. doi: 10.1093/rheumatology/key054.

PMID:
29538755
4.

Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis.

Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC.

Rheumatology (Oxford). 2018 Apr 1;57(4):769. doi: 10.1093/rheumatology/key007. No abstract available.

PMID:
29373696
5.

Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis.

Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC.

Rheumatology (Oxford). 2018 Apr 1;57(4):625-630. doi: 10.1093/rheumatology/kex471. Erratum in: Rheumatology (Oxford). 2018 Apr 1;57(4):769.

PMID:
29325173
6.

Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.

Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic MC.

Clin Rheumatol. 2017 Dec;36(12):2743-2750. doi: 10.1007/s10067-017-3848-6. Epub 2017 Oct 4.

7.

Activation of Complement by Pigment Epithelium-Derived Factor in Rheumatoid Arthritis.

Vogt LM, Talens S, Kwasniewicz E, Scavenius C, Struglics A, Enghild JJ, Saxne T, Blom AM.

J Immunol. 2017 Aug 1;199(3):1113-1121. doi: 10.4049/jimmunol.1700018. Epub 2017 Jun 21.

8.

Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy.

Nived P, Nagel J, Saxne T, Geborek P, Jönsson G, Skattum L, Kapetanovic MC.

Vaccine. 2017 Jun 22;35(29):3639-3646. doi: 10.1016/j.vaccine.2017.05.044. Epub 2017 May 25.

PMID:
28552512
9.

Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis.

Berthold E, Månsson B, Gullstrand B, Geborek P, Saxne T, Bengtsson AA, Kahn R.

Scand J Rheumatol. 2018 Jan;47(1):22-26. doi: 10.1080/03009742.2017.1290822. Epub 2017 May 9.

PMID:
28485187
10.

Quantification of cartilage oligomeric matrix protein (COMP) and a COMP neoepitope in synovial fluid of patients with different joint disorders by novel automated assays.

Lorenzo P, Aspberg A, Saxne T, Önnerfjord P.

Osteoarthritis Cartilage. 2017 Sep;25(9):1436-1442. doi: 10.1016/j.joca.2017.04.004. Epub 2017 May 2.

11.

Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.

Nagel J, Saxne T, Geborek P, Bengtsson AA, Jacobsen S, Svaerke Joergensen C, Nilsson JÅ, Skattum L, Jönsen A, Kapetanovic MC.

Lupus. 2017 Sep;26(10):1072-1081. doi: 10.1177/0961203317695465. Epub 2017 Feb 26.

PMID:
28420056
12.

Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.

Kapetanovic MC, Nagel J, Nordström I, Saxne T, Geborek P, Rudin A.

Vaccine. 2017 Feb 7;35(6):903-908. doi: 10.1016/j.vaccine.2016.12.068. Epub 2017 Jan 9.

PMID:
28081972
13.

Pentraxin 3 in serum and synovial fluid of patients with rheumatoid arthritis with and without autoantibodies.

Weitoft T, Larsson A, Saxne T, Manivel VA, Lysholm J, Knight A, Rönnelid J.

Scand J Rheumatol. 2017 Sep;46(5):346-352. doi: 10.1080/03009742.2016.1244288. Epub 2016 Dec 15.

PMID:
27973973
14.

Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective.

Kapetanovic MC, Hameed M, Turkiewicz A, Neogi T, Saxne T, Jacobsson L, Englund M.

RMD Open. 2016 Nov 1;2(2):e000326. eCollection 2016.

15.

Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis.

Okrój M, Johansson M, Saxne T, Blom AM, Hesselstrand R.

Arthritis Res Ther. 2016 Nov 18;18(1):267.

16.

The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis.

Struglics A, Okroj M, Swärd P, Frobell R, Saxne T, Lohmander LS, Blom AM.

Arthritis Res Ther. 2016 Oct 6;18(1):223.

17.

Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.

Einarsson JT, Geborek P, Saxne T, Kristensen LE, Kapetanovic MC.

J Rheumatol. 2016 Jun;43(6):1017-23. doi: 10.3899/jrheum.150995. Epub 2016 Apr 1.

PMID:
27036384
18.

Limited impact of fibromodulin deficiency on the development of experimental skin fibrosis.

Andréasson K, Gustafsson R, Rydell-Törmänen K, Westergren-Thorsson G, Saxne T, Hesselstrand R.

Exp Dermatol. 2016 Jul;25(7):558-61. doi: 10.1111/exd.13012.

PMID:
26997256
19.

Diet-Induced Arthritis in Pigs: Comment on the Article by Scher et al.

Andréasson K, Marsal J, Månsson B, Saxne T, Wollheim FA.

Arthritis Rheumatol. 2016 Jun;68(6):1568-9. doi: 10.1002/art.39642. No abstract available.

20.

Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.

Kahn R, Berthold E, Gullstrand B, Schmidt T, Kahn F, Geborek P, Saxne T, Bengtsson AA, Månsson B.

Acta Paediatr. 2016 Apr;105(4):427-32. doi: 10.1111/apa.13319. Epub 2016 Feb 1.

21.

Cartilage oligomeric matrix protein: a new promising biomarker of liver fibrosis in chronic hepatitis C.

Andréasson K, Hesselstrand R, Saxne T, Holmberg A, Norrgren H, Jönsson G.

Infect Dis (Lond). 2015;47(12):915-8. Epub 2015 Aug 12.

PMID:
26269256
22.

The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.

Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, Nilsson JÅ, Truedsson L, Kapetanovic MC.

Arthritis Res Ther. 2015 May 19;17:124. doi: 10.1186/s13075-015-0636-z.

23.

Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.

Einarsson JT, Geborek P, Saxne T, Kapetanovic MC.

J Rheumatol. 2015 May;42(5):741-8. doi: 10.3899/jrheum.131502. Epub 2015 Feb 15.

PMID:
25684762
24.

The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.

Nagel J, Geborek P, Saxne T, Jönsson G, Englund M, Petersson IF, Nilsson JÅ, Kapetanovic MC.

Scand J Rheumatol. 2015;44(4):271-9. doi: 10.3109/03009742.2014.984754. Epub 2015 Feb 6.

PMID:
25656734
25.

Recurrent fever caused by Candidatus Neoehrlichia mikurensis in a rheumatoid arthritis patient treated with rituximab.

Andréasson K, Jönsson G, Lindell P, Gülfe A, Ingvarsson R, Lindqvist E, Saxne T, Grankvist A, Wennerås C, Marsal J.

Rheumatology (Oxford). 2015 Feb;54(2):369-71. doi: 10.1093/rheumatology/keu441. Epub 2014 Nov 20. No abstract available.

PMID:
25416710
26.

Development of functional impairment and disability in rheumatoid arthritis patients followed for 20 years: relation to disease activity, joint damage, and comorbidity.

Kapetanovic MC, Lindqvist E, Nilsson JÅ, Geborek P, Saxne T, Eberhardt K.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):340-8. doi: 10.1002/acr.22458.

27.

Outcome predictors of intra-articular glucocorticoid treatment for knee synovitis in patients with rheumatoid arthritis - a prospective cohort study.

Weitoft T, Rönnelid J, Knight A, Lysholm J, Saxne T, Larsson A.

Arthritis Res Ther. 2014 Jun 20;16(3):R129. doi: 10.1186/ar4586.

28.

Novel cartilage oligomeric matrix protein (COMP) neoepitopes identified in synovial fluids from patients with joint diseases using affinity chromatography and mass spectrometry.

Åhrman E, Lorenzo P, Holmgren K, Grodzinsky AJ, Dahlberg LE, Saxne T, Heinegård D, Önnerfjord P.

J Biol Chem. 2014 Jul 25;289(30):20908-16.

29.

A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis.

Knevel R, de Rooy DP, Saxne T, Lindqvist E, Leijsma MK, Daha NA, Koeleman BP, Tsonaka R, Houwing-Duistermaat JJ, Schonkeren JJ, Toes RE, Huizinga TW, Brouwer E, Wilson AG, van der Helm-van Mil AH.

Arthritis Res Ther. 2014 May 7;16(3):R108. doi: 10.1186/ar4558.

30.

Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren's syndrome and rheumatoid arthritis.

Andréasson K, Saxne T, Scheja A, Bartosik I, Mandl T, Hesselstrand R.

Arthritis Res Ther. 2014 Feb 6;16(1):R46. doi: 10.1186/ar4475.

31.

Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.

Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Mörner A, Geborek P.

Arthritis Res Ther. 2014 Jan 2;16(1):R2. doi: 10.1186/ar4427.

32.

Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.

van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, Farina GA, Stifano G, Mathes AL, Cossu M, York M, Collins C, Wenink M, Huijbens R, Hesselstrand R, Saxne T, DiMarzio M, Wuttge D, Agarwal SK, Reveille JD, Assassi S, Mayes M, Deng Y, Drenth JP, de Graaf J, den Heijer M, Kallenberg CG, Bijl M, Loof A, van den Berg WB, Joosten LA, Smith V, de Keyser F, Scorza R, Lunardi C, van Riel PL, Vonk M, van Heerde W, Meller S, Homey B, Beretta L, Roest M, Trojanowska M, Lafyatis R, Radstake TR.

N Engl J Med. 2014 Jan 30;370(5):433-43. doi: 10.1056/NEJMoa1114576. Epub 2013 Dec 18.

33.

Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis.

Otteby KE, Holmquist E, Saxne T, Heinegård D, Hesselstrand R, Blom AM.

Arthritis Res Ther. 2013;15(6):R215.

34.

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.

Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P.

Arthritis Res Ther. 2013 Oct 30;15(5):R171. doi: 10.1186/ar4358.

35.

COMP-C3b complexes in rheumatoid arthritis with severe extraarticular manifestations.

Happonen KE, Saxne T, Jacobsson L, Sturfelt G, Rönnelid J, Mollnes TE, Heinegård D, Turesson C, Blom AM.

J Rheumatol. 2013 Dec;40(12):2001-5. doi: 10.3899/jrheum.130613. Epub 2013 Nov 1.

PMID:
24187101
36.

Association of genetic variants in the IL4 and IL4R genes with the severity of joint damage in rheumatoid arthritis: a study in seven cohorts.

Krabben A, Wilson AG, de Rooy DP, Zhernakova A, Brouwer E, Lindqvist E, Saxne T, Stoeken G, van Nies JA, Knevel R, Huizinga TW, Toes R, Gregersen PK, van der Helm-van Mil AH.

Arthritis Rheum. 2013 Dec;65(12):3051-7. doi: 10.1002/art.38141.

37.

Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.

Kristensen LE, Bliddal H, Christensen R, Karlsson JA, Gülfe A, Saxne T, Geborek P.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):173-9. doi: 10.1002/acr.22107.

38.

Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis.

Andersson ML, Svensson B, Petersson IF, Hafström I, Albertsson K, Forslind K, Heinegård D, Saxne T.

BMC Musculoskelet Disord. 2013 Aug 2;14:229. doi: 10.1186/1471-2474-14-229.

39.

Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria.

Andréasson K, Saxne T, Bergknut C, Hesselstrand R, Englund M.

Ann Rheum Dis. 2014 Oct;73(10):1788-92. doi: 10.1136/annrheumdis-2013-203618. Epub 2013 Jul 29.

PMID:
23897770
40.

Associations between APOE genotypes and disease susceptibility, joint damage and lipid levels in patients with rheumatoid arthritis.

Maehlen MT, Provan SA, de Rooy DP, van der Helm-van Mil AH, Krabben A, Saxne T, Lindqvist E, Semb AG, Uhlig T, van der Heijde D, Mero IL, Olsen IC, Kvien TK, Lie BA.

PLoS One. 2013 Apr 17;8(4):e60970. doi: 10.1371/journal.pone.0060970. Print 2013.

41.

Relationships amongst osteoarthritis biomarkers, dynamic knee joint load, and exercise: results from a randomized controlled pilot study.

Hunt MA, Pollock CL, Kraus VB, Saxne T, Peters S, Huebner JL, Sayre EC, Cibere J.

BMC Musculoskelet Disord. 2013 Mar 27;14:115. doi: 10.1186/1471-2474-14-115.

42.

A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis.

Knevel R, Krabben A, Wilson AG, Brouwer E, Leijsma MK, Lindqvist E, de Rooy DP, Daha NA, van der Linden MP, Tsonaka S, Zhernakova A, Westra HJ, Franke L, Houwing-Duistermaat JJ, Toes RE, Huizinga TW, Saxne T, van der Helm-van Mil AH.

Arthritis Rheum. 2013 Mar;65(3):582-9. doi: 10.1002/art.37808.

43.
44.

Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis.

de Rooy DP, Yeremenko NG, Wilson AG, Knevel R, Lindqvist E, Saxne T, Krabben A, Leijsma MK, Daha NA, Tsonaka S, Zhernakova A, Houwing-Duistermaat JJ, Huizinga TW, Toes RE, Baeten DL, Brouwer E, van der Helm-van Mil AH.

Ann Rheum Dis. 2013 May;72(5):769-75. doi: 10.1136/annrheumdis-2012-202184. Epub 2012 Oct 5. Erratum in: Ann Rheum Dis. 2015 Jan;74(1):319.

PMID:
23041840
45.

Interactions of the complement system with molecules of extracellular matrix: relevance for joint diseases.

Happonen KE, Heinegård D, Saxne T, Blom AM.

Immunobiology. 2012 Nov;217(11):1088-96. doi: 10.1016/j.imbio.2012.07.013. Review.

PMID:
22964234
46.

Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome.

Foltyn Zadura A, Zipfel PF, Bokarewa MI, Sturfelt G, Jönsen A, Nilsson SC, Hillarp A, Saxne T, Trouw LA, Blom AM.

Arthritis Res Ther. 2012 Aug 15;14(4):R185. doi: 10.1186/ar4016.

47.

Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts.

Knevel R, de Rooy DP, Gregersen PK, Lindqvist E, Wilson AG, Gröndal G, Zhernakova A, van Nies JA, Toes RE, Tsonaka R, Houwing-Duistermaat JJ, Steinsson K, Huizinga TW, Saxne T, van der Helm-van Mil AH.

Ann Rheum Dis. 2012 Oct;71(10):1753-5. doi: 10.1136/annrheumdis-2012-201289. Epub 2012 May 14. No abstract available. Erratum in: Ann Rheum Dis. 2012 Dec;71(12):2064.

PMID:
22586175
48.

Heavy chains of inter alpha inhibitor (IαI) inhibit the human complement system at early stages of the cascade.

Okroj M, Holmquist E, Sjölander J, Corrales L, Saxne T, Wisniewski HG, Blom AM.

J Biol Chem. 2012 Jun 8;287(24):20100-10. doi: 10.1074/jbc.M111.324913. Epub 2012 Apr 23.

49.

Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis.

Rydell-Törmänen K, Andréasson K, Hesselstrand R, Risteli J, Heinegård D, Saxne T, Westergren-Thorsson G.

Lab Invest. 2012 Jun;92(6):917-25. doi: 10.1038/labinvest.2012.57. Epub 2012 Apr 2.

50.

[Rheumatologic research with animal experiments is important for our patients].

Rudin A, Sturfelt G, Carlsten H, Hafström I, Lundberg I, Klareskog L, Rönnblom L, Jacobsson L, van Vollenhoven R, Rantapää-Dahlqvist S, Skogh T, Saxne T.

Lakartidningen. 2012 Jan 11-17;109(1-2):40. Swedish. No abstract available.

PMID:
22468412

Supplemental Content

Support Center